Filtering

DOP06 Non-invasive identification of adherent-invasive E. coli in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

A. Buisson1, E. Vazeille1, X. Hébuterne2, M. Fumery3, B. Pariente4, S. Nancey5, P. Seksik6, L. Peyrin-Biroulet7, M. Allez8, N. Ballet9, E. Billard10, S. Rodriguez10, B. Pereira11, N. Barnich10, CEALIVE Study Group

1Department of Digestive and Hepatobiliary Medicine, Department of Gastroenterology, CHU Estaing, Clermont-Ferrand, France, 2CHU Nice, Department of Gastroenterology, Nice, France, 3Department of Gastroenterology, CHu Amiens, Amiens, France, 4Department of Gastroenterology, CHU Lille, Lille, France, 5Department of Gastroenterology, CHU Lyon-Sud, Lyon, France, 6Department of Gastroenterology, CHU Saint-Antoine, Paris, France, 7Department of Gastroenterology, CHU Nancy, Nancy, France, 8Department of Gastroenterology, Saint-Louis Hospital, Paris, France, 9Lesafre Company, France, France, 10U1071 Inserm UCA, M2iSH, Clermont-Ferrand, France, 11CHU, Biostatistics Unit, Clermont-Ferrand, France

DOP07 Long-term results of 4.5 years of faecal microbiota transplantation for treatment of refractory ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Uygun1, M.F. Karakaya1, H. Erdal1, G. Celebi1, Y.S. Sakin1, C. Artuk2, K. Ozturk1, M. Gulsen1

1Department of Gastroenterology, Gulhane Faculty of Medicine, Ankara, Turkey, 2Department of Infectious Diseases and Clinical Microbiology, Gulhane Faculty of Medicine, Ankara, Turkey

DOP08 Deep remission in paediatric Crohn’s disease is associated with increased abundance of dialister species and increased valerate

ECCO'20 Vienna

Year: 2020
Authors:

H. Taylor1, J. McDonald1, J.I. Serrano Contreras1, J. Li1, J. Marchesi1, A. Hart1,2

1Department of Medicine, Imperial College London, London, UK, 2Inflammatory Bowel Disease Unit, St Mark’s Academic Institute, London, UK

DOP09 IgG responses to multiple bacterial flagellins identify a subgroup of paediatric therapy-naive Crohn’s disease patients with increased microbiota-specific T-cell reactivity

ECCO'20 Vienna

Year: 2020
Authors:

L. Costes1, I. Tindemans1, M.E. Joosse1, M.A. Aardoom2, M.M.E. Jongsma2, R.H.C. Raatgeep1, D.H. van Haaften1, K.L. Alexander3, L.W. Duck3, A.P. Heikema4, P. Kemos5, J.C. Escher2, F.M. Ruemmele6, N.M. Croft7, C.O. Elson8, L. de Ridder2, J.N. Samsom1

1Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands, 2Department of Pediatric Gastroenterology, Erasmus University Medical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands, 3Departments of Immunology, University of Alabama at Birmingham, Birmingham, USA, 4Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands, 5Blizard Institute, Queen Mary University of London, London, UK, 6Service de Gastroentérologie, Sorbonne Paris Cité- APHP, Hôpital Necker Enfants Malades, Université Paris Descartes, Paris, France, 7Centre for Digestive Diseases, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK, 8Department of Medicine, University of Alabama at Birmingham, Birmingham, USA

DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy

ECCO'20 Vienna

Year: 2020
Authors:

T. Kucharzik1, R. Wilkens2,3, G. Maconi4, M.A. D’Agostino5, M. Le Bars6, M. Nazar7, S. Sloan8, M. Lahaye9, L. Ni10, E. Ercole11, M. Alloca12, N. Machková13, C. Maaser14

1Klinik für Allgemeine Innere Medizin und Gastroenterologie, Klinikum Lüneburg, Lüneburg, Germany, 2Gastro Unit Section of Medicine, Hvidovre Hospital, Copenhagen, Denmark, 3Digestive Disease Center, Bispebjerg Hospital, Copenhagen, Denmark, 4Gastroenterology Unit, Department of Biomedical and Clinical Sciences, ‘Luigi Sacco’ University Hospital University of Milan, Milan, Italy, 5Ambroise Paré Hospital APHP-Paris Saclay, University INSERM U1173 Laboratoire d’Excellence INFLAMEX, Rheumatology Department, Paris, France, 6Department of Medical Affairs, Janssen-Cilag SARL, Issy-les-Moulineaux, France, 7Department of Medical Affairs, Janssen-Cilag Polska Sp. z o.o, Warsaw, Poland, 8Department of Medical Affairs, Janssen Scientific Affairs LLC, Horsham, PA, USA, 9Department of Medical Affairs, Janssen-Cilag B.V., Breda, The Netherlands, 10Department of Medical Affairs, Janssen-Cilag, Moscow, Russian Federation, 11Gastroenterology Unit, Mauriziano Hospital, Turin, Italy, 12Department of Gastroenterology, Humanitas University, Milan, Italy, 13Clinical Center ISCARE, Clinical and Research Center for Inflammatory Bowel Diseases, Prague, Czech Republic, 14Ambulanzzentrum Gastroenterologie, Klinikum Lüneburg, Lüneburg, Germany

DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

N. Plevris, J. Fulforth, P. Jenkinson, M. Lyons, C. Chuah, S. Siakavellas, R. Pattenden, I. Arnott, G. Jones, C. Lees

The Edinburgh IBD Unit, Gastroenterology, Western General Hospital, Edinburgh, UK

DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension

ECCO'20 Vienna

Year: 2020
Authors:

R. Panaccione1, W.J. Sandborn2, B.E. Sands3, C. Marano4, C.D. O’Brien4, H. Zhang5, J. Johanns5, Y. Zhou5, L. Peyrin-Biroulet6, T. Hisamatsu7, S. Danese8, UNIFI Investigators

1University of Calgary, Inflammatory Bowel Disease Center, Calgary, Canada, 2University of California San Diego, Gastroenterology, La Jolla, USA, 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, USA, 4Janssen Research and Development- LLC, Immunology, Spring House, USA, 5Janssen Research and Development- LLC, Clinical Biostats, Spring House, USA, 6Nancy University Hospital, Gastroenterology, Nancy, France, 7Kyorin University School of Medicine, Internal Medicine, Tokyo, Japan, 8Humanitas Research Hospital, Gastroenterology, Milan, Italy

DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial

ECCO'20 Vienna

Year: 2020
Authors:

S. Danese1, S. Vermeire2, G. D’Haens3, J. Panés4, A. Dignass5, F. Magro6, M. Nazar7, M. Le Bars8, S. Sloan9, M. Lahaye10, L. Ni11, M. Daperno12, M. Lukáš13, A. Armuzzi14, M. Löwenberg3, D.R. Gaya15, L. Peyrin-Biroulet16

1Humanitas University, Department of Gastroenterology, Milan, Italy, 2University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 3University of Amsterdam, Academic Medical Centre, Amsterdam, The Netherlands, 4Hospital Clinic of Barcelona CIBERehd, Department of Gastroenterology, Barcelona, Spain, 5Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany, 6Department of Pharmacology and Therapeutics, Institute for Molecular and Cell Biology, Faculty of Medicine, University of Porto, and Department of Gastroenterology, Hospital de Sao Joao, Porto, Portugal, 7Janssen-Cilag Polska Sp. z o.o, Medical Affairs, Warsaw, Poland, 8Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France, 9Janssen Global Services LLC, Medical Affairs, Horsham, PA, USA, 10Janssen-Cilag B.V., Medical Affairs, Breda, The Netherlands, 11Janssen-Cilag Russia, Medical Affairs, Moscow, Russian Federation, 12Mauriziano Hospital, Gastroenterology Unit, Turin, Italy, 13Clinical Center ISCARE, Clinical and Research Center for Inflammatory Bowel Diseases, Prague, Czech Republic, 14Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, IBD Unit Presidio Columbus, Rome, Italy, 15Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, UK, 16University Hospital of Nancy University of Lorraine, INSERM Unité 954 and Department of Hepato-Gastroenterology, Houdemont, France

DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

E. Dreesen1, S. Berends2, D. Laharie3, G. D’Haens4, S. Vermeire5, A. Gils1, R. Mathôt2

1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 2Department of Hospital Pharmacy, Amsterdam UMC, Amsterdam, The Netherlands, 3Hepato-gastroenterology and Digestive Oncology, Haut-Lévêque Hospital- Bordeaux UMC, Bordeaux, France, 4Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands, 5Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Rimola1, J.F. Colombel2, B. Bressler3, S. Adsul4, J. Siegelman5, P.E. Cole6, D. Lindner7, S. Danese8

1Department of Radiology, Hospital Clínic de Barcelona, Barcelona, Spain, 2Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, USA, 3Division of Gastroenterology-, University of British Columbia, Vancouver, Canada, 4Takeda, Global Medical Affairs, Zurich, Switzerland, 5Clinical Development and Clinical Translation, Takeda, Cambridge, USA, 6Takeda, Department of Imaging, Cambridge, USA, 7Takeda, Statistical and Quantitative Sciences, Zurich, Switzerland, 8Department of Gastrointestinal Immunopathology, Humanitas University, Milan, Italy

DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2

ECCO'20 Vienna

Year: 2020
Authors:

C. Chen1, M. Rosario2, D. Polhamus3, N. Dirks3, W. Zhang4, W. Sun1, K. Kisfalvi5, B. Feagan6, W. Sandborn7, S. Vermeire8, G. D’Haens9

1Takeda, Quantitative Clinical Pharmacology, Cambridge, USA, 2Takeda, Clinical Pharmacology, Deerfield, USA, 3Metrum Research Group, Tariffville, USA, 4Takeda, Statistical and Quantitative Sciences, R&D, Cambridge, USA, 5Takeda, Research and Development, Global Clinical Sciences, Cambridge, USA, 6Western University, Robarts Clinical Trials, London, Ontario, Canada, 7Division of Gastroenterology, University of California San Diego, La Jolla, USA, 8Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 9Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands

DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study

ECCO'20 Vienna

Year: 2020
Authors:

S. Vermeire1, H. Guay2, B. Verstockt3, J. Fann4, J. Cheng4, F. Hong4, W.J. Lee5, A. Lacerda6, W. Zhou6, S. Danese7

1Department of Translational Research Centre for GastroIntestinal Disorders TARGID, KU Leuven, Leuven, Belgium, 2Immunology Clinical Development, AbbVie Inc., Worcester, USA, 3Department of Chronic Diseases, Metabolism and Ageing, CHROMETA, KU Leuven, Leuven, Belgium, 4Discovery and Exploratory Statistics, AbbVie Inc., Worcester, USA, 5Health Economics and Outcomes Research HEOR, AbbVie Inc., Worcester, USA, 6Global Pharmaceutical Research and Development, AbbVie Inc., North Chicago, USA, 7Department of Gastroenterology, Instituto Clinico Humanitas, Milan, Italy

DOP18 Impact of adherence to anti-tumour necrosis factor therapy on clinical outcomes in Crohn’s disease: A nationwide population-based study

ECCO'20 Vienna

Year: 2020
Authors:

J.J. Park1, H. Koo2, Y. Park1, S.J. Park1, T.I. Kim1, W.H. Kim1, J.H. Cheon1, E.H. Han2

1Severance Hospital, Internal Medicine, Seoul, Korea Republic of, 2Yonsei Institute of Pharmaceutical Sciences, Yonsei University, College of Pharmacy, Incheon, Korea Republic of

DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months

ECCO'20 Vienna

Year: 2020
Authors:

B. Cohen1, H. Chang2, J.R. Jason Rogers1, S. Garg1, D. Lawrence3, F. Fasihuddin1, T. Lissoos4, A. Atreja5

1Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, 2Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA, 3Department of Gastroenterology, Takeda Pharmaceuticals, Deerfield, USA, 4Lilly Biomedicines, Eli Lilly & Company, Indianapolis, USA, 5Department of Gastroenterology, Mount Sinai, New York, USA

DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine

ECCO'20 Vienna

Year: 2020
Authors:

R.C.A. Lalisang1, G. Adriaans2, M. de Jong3, A. van der Meulen-de Jong4, M. Romberg-Camps5, N. Mahmmod6, T. Markus-de Kwaadsteniet7, G. Dijkstra8, J. Haans2, C. Stamm9, R. Vanwersch10, D. Jonkers11, R.J. Almeida12,13, M.J. Pierik2, MyIBDcoach Study Group

1Division of Gastroenterology and Hepatology, Maastricht Universitair Medisch Centrum+, Pacmed, Maastricht, The Netherlands, 2Division of Gastroenterology and Hepatology, Maastricht Universitair Medisch Centrum+, Maastricht, The Netherlands, 3Haga Ziekenhuis, Department of Gastroenterology, Den Haag, The Netherlands, 4Department of Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands, 5Department of Gastroenterology, Zuyderland Medical Centre, Sittard, The Netherlands, 6Department of Gastroenterology, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands, 7Stichting mijnIBDcoach, Board, Mijdrecht, The Netherlands, 8Department of Gastroenterology, Universitair Medisch Centrum Groningen, Groningen, The Netherlands, 9Department of Health Care, Pacmed, Amsterdam, The Netherlands, 10Information Systems, Faculty of Industrial Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands, 11Department of Internal Medicine, Division of Gastroenterology-Hepatology, University Maastricht, Maastricht, The Netherlands, 12Department of Quantitative Economics, School of Business and Economics, Maastricht University, Maastricht, The Netherlands, 13Department of Data Analytics and Digitalisation, Maastricht University, Maastricht, The Netherlands

DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study

ECCO'20 Vienna

Year: 2020
Authors:

M. Høivik1, M. Lördal2, J. Burisch3, E. Langholz4, T. Knudsen5, M. Voutilainen6, B. Moum1, K. Anisdahl1, B. Saebo7, P. Haiko8, C. Malmgren9, M. Coskun10, H.O. Melberg11

1Department of Gastroenterology, Oslo University Hospital, Oslo, Norway, 2Department of Gastroenterology and Hepatology, Danderyds Hospital, Stockholm, Sweden, 3Department of Gastrounit- Medical Division, Hvidovre University Hospital, Hvidovre, Denmark, 4Department of Medical Gastroenterology, Herlev Hospital, Herlev, Denmark, 5Department of Medicine, Hospital South West Denmark, Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, 6Department of Gastroenterology, University of Turku, Turku, Finland, 7Takeda AS, Medical Affairs, Asker, Norway, 8Takeda Oy, Medical Affairs, Helsinki, Finland, 9Department of Medical Affairs, Takeda Pharma AB, Stockholm, Sweden, 10Department of Medical Affairs, Taastrup, Denmark, 11Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway

DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)

ECCO'20 Vienna

Year: 2020
Authors:

M. Barreiro-de Acosta1, A. Gutierrez2, Y. Zabana3, B. Beltran4, X. Calvet5, M. Chaparro6, E. Domènech7, M. Esteve3, J. Panés8, J.P. Gisbert6, P. Nos4, on behalf of GETECCU

1Department of Gastroenterology- IBD Unit, University Hospital Santiago De Compostela CHUS, Santiago De Compostela, Spain, 2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gatroenterology, Hospital Universitario de Alicante, Alicante, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Hospital Universitari Mútua Terrassa, Terrasa, Spain, 4Centro de de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD-, Gastroenterology, Hospital Universitario La Fe, Valencia, Spain, 5Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Corporació Sanitaria Universitària Parc Taulí, Sabadell, Spain, 6Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa IIS-IP, Madrid, Spain, 7Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Germans Trias i Pujol, Badalona, Spain, 8Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Hospital Clinic, Gastroenterology, Barcelona, Spain

DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe

ECCO'20 Vienna

Year: 2020
Authors:

Z. Guo, Y. Zhu, L. Cao, Y. Li, Z. Wang, W. Zhu

Department of General Surgery, Jinling Hospital, Nanjing, China

DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial

ECCO'20 Vienna

Year: 2020
Authors:

E.V. Loftus Jr1, S.W. Schreiber2, S. Danese3, L. Peyrin-Biroulet4, J.F. Colombel5, B.E. Sands5, S. Wang6, J. Chen7, R.A. Lirio8

1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, USA, 2Department of Medicine, University Hospital Schleswig-Holstein, Kiel, Germany, 3Department of Gastrointestinal Immunopathology, Humanitas University, Milan, Italy, 4Department of Gastroenterology, Nancy University Hospital, Nancy, France, 5Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, 6Global Outcomes Research and Epidemiology, Takeda, Cambridge, USA, 7Statistics and Quantitative Sciences, Takeda, Cambridge, USA, 8Clinical Science, Takeda, Cambridge, USA

DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort

ECCO'20 Vienna

Year: 2020
Authors:

E. Barnes1, J. Hanson2, M. Regueiro3, S. Saha4, B.E. Sands5, D. Rubin6, M. Dubinsky7, C. Siegel8, D. Gazis9, J. Crawford10, M. Long1

1Department of Gastroenterology, University of North Carolina, Chapel Hill, USA, 2Department of Gastroenterology, Atrium Health, Charlotte, USA, 3Department of Gastroenterology, Cleveland Clinic, Cleveland, USA, 4Department of Gastroenterology, University of Wisconsin, Madison, USA, 5Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Medical Center, New York, USA, 6Department of Gastroenterology, University of Chicago, Chicago, USA, 7Department of Pediatric Gastroenterology and Nutrition, Mount Sinai School of Medicine, New York, USA, 8Department of Gastroenterology, Dartmouth Hitchcock, Lebanon, USA, 9Department of Statistics, TARGET PharmaSolutions, Durham, USA, 10Scientific and Medical Affairs, TARGET PharmaSolutions, Durham, USA